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Structure-activity relationship of FPH1. Structures of FPH1, its bare scaffold (4) and a series of its analogs (5-10) tested during primary screening suggest that a 5-chloro-2-methyl substituted sulfonamido phenyl ring and a phenylamide ring without significant steric bulk at the para position are required for compound activity. Six additional sources of primary human hepatocytes were treated with FPHs and A) stained for albumin (green) and Ki67 (red) after 6 days in culture. Scale bars represent 300um. B) Day 1 untreated control was added for reference (top). On day 7, we quantified the number of hepatocytes in culture using FACS analysis. Supplementary Fig. 7 Functional analysis of FPH-treated primary human hepatocytes. A, gene expression profiling of FPH-treated human hepatocytes. A panel of 83 liver-specific genes were analyzed via Luminex. Columns of the heatmap are averaged values of replicate (n=3) loadings of mRNA extracted from various populations of human hepatocytes (250ng total RNA per replicate). mRNA expression was determined relative to the average of control gene transferrin, and heat maps are row-normalized. Bar graphs are select gene sets comparing the relative mRNA expression of FPH-treated hepatocytes (patterned bars) and HepG2 (solid red bar), normalized to primary human hepatocytes (solid black bar) for nuclear receptors, phase I, phase II, and phase III drug metabolism genes. Data represent the mean ± SEM of Luminex-loaded replicates. B, phase 3 transporter activity. Cultures were incubated with 5-(and-6)-carboxy-2',7'-dichlorofluorescein diacetate, which is internalized by hepatocytes, cleaved by intracellular esterases and excreted into the bile canaliculi between hepatocytes by transporters (scale bar = 50um). C, biochemical characterization of key hepatocyte functions. Albumin secretion reflects protein synthesis capability; urea content is a surrogate marker for protein metabolism; detoxification functions were measured via processing of substrate BFC into fluorescent products. For all analyses, primary and FPH-treated hepatocytes were cultured for 7 days in 12-well plates (n=3). Control cultures were treated with empty vehicles (DMSO). All data presented as mean ± s.d.
